{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/OVID/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T17:09:49.571Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4048,"canonical_name":"Ovid Therapeutics Inc.","cik":"0001636651","uei":null,"lei":null,"duns":null,"ticker":"OVID"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":22},"count":22,"timeline":[{"ts":"2026-08-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Ovid Therapeutics Inc. — 2026-08-14","url_slug":"/sec/cik-0001636651/schedule-13g-a/0001104659-26-097342","accession_number":"0001104659-26-097342","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Ovid Therapeutics Inc. — 2026-08-13","url_slug":"/sec/cik-0001636651/10-q/0001628280-26-056498","accession_number":"0001628280-26-056498","importance":45},{"ts":"2026-08-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Ovid Therapeutics Inc. — 2026-08-13","url_slug":"/sec/cik-0001636651/8-k/0001628280-26-056497","accession_number":"0001628280-26-056497","importance":35},{"ts":"2026-08-13","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Ovid Therapeutics Inc. — 2026-08-13","url_slug":"/sec/cik-0001636651/schedule-13g-a/0001011438-26-000510","accession_number":"0001011438-26-000510","importance":30},{"ts":"2026-07-29","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Ovid Therapeutics Inc. — 2026-07-29","url_slug":"/sec/cik-0001636651/schedule-13g/0002012383-26-002922","accession_number":"0002012383-26-002922","importance":55},{"ts":"2026-07-08","kind":"sec.filing","form_type":"8-K","title":"8-K — Ovid Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0001636651/8-k/0001628280-26-047584","accession_number":"0001628280-26-047584","importance":35},{"ts":"2026-07-08","kind":"sec.filing","form_type":"3","title":"3 — Ovid Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0001636651/3/0001779359-26-000002","accession_number":"0001779359-26-000002","importance":30},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Ovid Therapeutics Inc. — 2026-07-08","url_slug":"/sec/cik-0001636651/4/0001779359-26-000004","accession_number":"0001779359-26-000004","importance":30},{"ts":"2026-07-06","kind":"sec.insider.a","reporter":"Carter Charles Ross","title":"Chief Financial Officer","shares":50000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-17","kind":"sec.filing","form_type":"3","title":"3 — Ovid Therapeutics Inc. — 2026-06-17","url_slug":"/sec/cik-0001636651/3/0002138163-26-000003","accession_number":"0002138163-26-000003","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Ovid Therapeutics Inc. — 2026-06-17","url_slug":"/sec/cik-0001636651/4/0002138163-26-000005","accession_number":"0002138163-26-000005","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Ovid Therapeutics Inc. — 2026-06-11","url_slug":"/sec/cik-0001636651/8-k/0001628280-26-042396","accession_number":"0001628280-26-042396","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"8-K","title":"8-K — Ovid Therapeutics Inc. — 2026-06-03","url_slug":"/sec/cik-0001636651/8-k/0001628280-26-040038","accession_number":"0001628280-26-040038","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Ovid Therapeutics Inc. — 2026-05-15","url_slug":"/sec/cik-0001636651/schedule-13g/0000919574-26-003209","accession_number":"0000919574-26-003209","importance":55},{"ts":"2026-05-14","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Ovid Therapeutics Inc. — 2026-05-14","url_slug":"/sec/cik-0001636651/schedule-13g-a/0001011438-26-000317","accession_number":"0001011438-26-000317","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Ovid Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0001636651/10-q/0001628280-26-033864","accession_number":"0001628280-26-033864","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Ovid Therapeutics Inc. — 2026-05-12","url_slug":"/sec/cik-0001636651/8-k/0001628280-26-033859","accession_number":"0001628280-26-033859","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Ovid Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0001636651/def-14a/0001628280-26-027621","accession_number":"0001628280-26-027621","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"424B3","title":"424B3 — Ovid Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0001636651/424b3/0001193125-26-182352","accession_number":"0001193125-26-182352","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Ovid Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0001636651/ars/0001628280-26-027625","accession_number":"0001628280-26-027625","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Ovid Therapeutics Inc. — 2026-04-27","url_slug":"/sec/cik-0001636651/defa14a/0001628280-26-027624","accession_number":"0001628280-26-027624","importance":30},{"ts":"2026-04-24","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Ovid Therapeutics Inc. — 2026-04-24","url_slug":"/sec/cik-0001636651/effect/9999999995-26-001333","accession_number":"9999999995-26-001333","importance":30}]}